Table 2.

Clinical trials that evaluated HAI oxaliplatin in patients with unresectable liver metastases from colo-rectal cancer.

Reference	Phase of Study	No.of Patients	Previous Treatments	Dose	Systemic Chemotherapy Associated	ORR	mPFS	mOS
Kern et al. 2001 [43]	I	21	Yes or No	25 mg/m2 with increments of 25 mg/m2	FUFA	59%	n.e.	n.e.
Mancuso et al. 2003 [49]	I	17	Yes	20 mg/m2/day x 5 days every 3 weeks	None	67%	n.e.	19
Fiorentini et al. 2004 [50]	I-II	12	Yes	150 mg/m2 every 3 weeks	None or FUFA ±Irinotecan	50%	4 m	13 m
Ducreux et al. 2005 [51]	II	26	None or first line of IV CT without oxal	100 mg/m2 every 2 weeks	FUFA	64%	27 m	27 m
Boige et al. 2007 [52]	II	44	Yes (> two lines)	100 mg/m2 every 2 weeks	FUFA	55%	7 m	16 m
Tsimberidou et al. 2010 [53]	I	29	Yes (> two lines)	60-175 mg/m2 every 2 weeks	FUFA plus bevacizumab	43%	n.e.	n.e.
Tsimberidou et al.2013 [54]	I	58	Yes	140 mg/m2 every 3 weeks	FUFA+bevacizumab/cetuximab	12% (KRAS negative) 6% (KRAS positive)	n.e.	12 m (KRAS negative)7 m (KRAS positive)
Allard et al. 2015 [55]	II	68	No	100 mg/m2 every 2 weeks	FUFA+cetuximab	n.e.	n.e.	114 m
Volovat et al. 2016 [56]	II	24	Yes or no	85 mg/m2 every 2 weeks	FOLFIRI	78%	20 m	29 m
Lévi et al. 2016 [57]	II	64	Yes	85 mg/m2 every 2 weeks	HAI irinotecan 180 mg/m2+5-FU 2800 mg/m2 plus IV cetuximab	41%	9 m	26 m
Lim et al. 2017 [58]	MCS	61	Yes or no	every 2 weeks	FUFA+bevacizumab/cetuximab	11–27%	9–6 m	14–8 m
Sato et al. 2018 [59]	I-II	13	Yes	50-100 mg/m2 every 2 weeks	FUFA	70%	n.e.	7 m

FUFA, 5-FU and folinic acid; n.e., not evaluated; m, months; FOLFIRI, 5-fluorouracil, folinic acid, irinotecan.